| Name | Title | Contact Details |
|---|
Over 26 million Americans suffer from chronic kidney disease (CKD), including 1.5 million New Yorkers. Formed in 1972 as a philanthropic gift of Edwin and Rhoda Sperber, the Foundation provides services to patients, family members, the general public and clinical and academic professionals throughout the Northeast. The mission of the Northeast Kidney Foundation is to improve the quality of life of those affected by kidney disease and related conditions through early identification, intervention, prevention and support services; to promote organ donation; and to empower those we serve to be an effective voice for better healthcare at the local, state and federal levels.
Nutricia North America is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
We believe affordable, convenient vision prescriptions are a good thing. We started Opternative to provide a safe, online option for vision testing. It`s a way to get prescriptions between eye exams. Eyes stay healthy. People can see clearly. It`s a win-win.
Smart devices and digital support that connect patients to care, with clinically-proven results https://t.co/zoMxznOfwA